Moderna has just announced the launch of the first clinical trial for an HIV vaccine made using its messenger RNA (mRNA) technology, and the first doses have
IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. The Phase 1 .
Gado/Getty Images(WASHINGTON) Moderna announced Thursday that it's launched early-stage clinical trials of an HIV mRNA vaccine. The biotechnology company has teamed up with the nonprofit International AIDS Vaccine Initiative to develop the shot, which uses the same technology as Moderna's successful COVID-19 vaccine. The first participants in the Phase I trial were given doses at George Washington University School of Medicine and Health Sciences in Washington, D.C., according to a company statement. "We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna's mRNA platform," Dr. Mark Feinberg, president and CEO of IAVI, said in a statement. "The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine." Nearly 38 million people worldwide including about 1
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA TechnologyPhase 1 trial aims to build on response seen in proof-of-concept trialCAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and biotechnology company Moderna an.